SEC
DNLI icon

Seven Eight Capital’s Denali Therapeutics DNLI Stock Holding History

Seven Eight Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,541
Closed -$422K – 750
2024
Q1 		$422K Sell
20,541
-52,046
-72% -$978K 0.04% 480
2023
Q4 		$1.56M Buy
+72,587
New +$1.44M 0.18% 168

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Seven Eight Capital's DNLI Position: Q2 2024 in Review

Seven Eight Capital sold out of Denali Therapeutics (DNLI) in Q2 2024, closing a stake of 20,541 shares — an estimated $422K sold.

Seven Eight Capital first reported a position in DNLI in Q4 2023 and held it in 2 quarters. The position peaked at $1.56M in Q4 2023. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2024.

  • Seven Eight Capital reported no remaining Denali Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Seven Eight Capital sold 20,541 Denali Therapeutics shares in Q2 2024, an estimated $422K.
  • Seven Eight Capital first reported a position in Denali Therapeutics in Q4 2023 and held it in 2 quarters.
  • Seven Eight Capital's Denali Therapeutics position peaked at $1.56M in Q4 2023.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2024.

Based on Seven Eight Capital's 13F filing for Q2 2024, filed 12 Aug 2024.